- Home
- >
- Our Thinking
- >
- Trending Topics
- >
- Britain & The European Union: Brexit Resource Centre
Britain & The European Union: Brexit Resource Centre
Following its departure from the European Union on 31 January 2020, the United Kingdom left the EU single market and customs union on 31 December 2020 under the terms of new trade deal announced on 24 December 2020. View the full agreement, and a summary of the terms.
This brings significant legal and regulatory issues for corporations, financial institutions, and individuals. Morgan Lewis's team of lawyers in London, the rest of Europe, and beyond are advising clients on legal and regulatory developments and the anticipated impact of Brexit. Particular areas of focus include banking and finance, financial regulation, employment, immigration, data protection, tax, antitrust, litigation, and arbitration.
Please contact members of our Brexit team, or email brexit@morganlewis.com if you have any questions.
Brexit Team
|
Competition
Frances Murphy
|
Immigration
Jennifer Connolly
|
Tax
Kate Habershon
|
|
Data Privacy
Pulina Whitaker
|
Intellectual Property
Anita Polott (Washington, D.C.) |
Middle East/
Ayman Khaleq (Dubai)
Investment Funds |
|
Employment
Matthew Howse
|
Investment Management
Simon CurrieWilliam Yonge |
US/ANTITRUST
Richard Taffet (New York)
|
|
Finance
Bruce Johnston
|
Litigation
Peter Sharp
|
|
|
FinTech
Torsten Schwarze |
Structured Transactions
Lisa Cargill |
Lawflashes/Articles
The European Commission has finally approved two decisions on 28 June granting the United Kingdom the cherished status of having “adequate” data protection laws so that transfers of personal data from the European Union are not restricted. The decisions follow months of negotiations after the Brexit transitional period ended on 31 December 2020 and before the temporary adequacy bridge is due to end on 30 June 2021.
Following Brexit, EU competition law continued to apply in the United Kingdom until 31 December 2020 as part of an agreed Transition Period. In this LawFlash, we summarise how the end of the Transition Period is likely to impact the enforcement of competition law in the United Kingdom going forward, the extent to which UK competition agencies and courts are free to diverge from EU principles and case law, and our initial thoughts on the future landscape of competition law in the United Kingdom.
The European Data Protection Board (EDPB) has finally released its much anticipated guidance following the Schrems II decision in July 2020, which invalidated the "Privacy Shield" system that allowed the transfer of personal data to the United States. EDPB also released draft new Standard Contractual Clauses (SCCs) that allow for data transfers from processors who are exporters as well as new SCCs for controllers who are exporters.
Coinciding with the end of the UK-EU Brexit transition period, the United Kingdom has dramatically reduced the scope of DAC 6 reporting obligations in the United Kingdom.
Lawyers from our London practice have contributed to Lexology’s Getting the Deal Through (GTDT) – Distressed M&A 2021 guide. The UK chapter features insight from lawyers in our corporate, finance, tax, and antitrust practices.
From 1 January 2021 the United Kingdom will cease to follow EU rules, bringing significant changes to trademark law in the United Kingdom and European Union that are relevant to all owners of UK and EU trademarks.
Paul Ranson examines how the UK Biopharma sector must now adapt to a changing landscape following the UK’s vote to leave the EU.
The Brexit “transition period” will come to an end on 31 December 2020, and from 1 January 2021, the United Kingdom will cease to follow EU rules. This brings significant changes to design law in the United Kingdom and European Union, relevant to all owners of Registered
The UK’s Competition and Markets Authority (CMA) on 6 November published draft updates to two of its merger guidance documents (CMA2 and CMA56) in preparation for the end of the Brexit Transition Period on 31 December 2020.
The UK government has now published a Statement of Changes setting out the rules for the new UK immigration system. Applications under the new system will open on December 1, 2020 for non-EEA nationals. EEA nationals will be eligible to apply from within the United Kingdom from January 1, 2021, and when they apply for entry clearance, it will be granted with effect from January 1, 2021. Irish nationals will not require a visa or permission to work.
The UK government and the Competition and Markets Authority (CMA) have announced the withdrawal of draft guidance on the CMA’s powers and procedures with respect to enforcing an EU regulation for screening foreign direct investment (FDI) into the European Union.
As noted in our recent LawFlashes, New Powers for UK Government in Transactions Impacting Public Health Emergencies and National Security and Potential UK Reforms Could Increase Screening of Certain Foreign Takeovers, governments are increasing their scrutiny of certain foreign direct investments (FDIs) and enhancing their FDI screening mechanisms.
The UK government has published further details outlining its plans for a new immigration system to take effect on January 1, 2021, when free movement within the European Economic Area and Swiss Economic Area (collectively, EEA) will end. This document builds on the policy statement released in February 2020 and provides more detail to applicants, employers, and educational institutions.
The UK government has published a policy paper detailing its new points-based immigration system, as well as updates on right to work checks for EEA nationals and guidance for individuals unable to return to China from the United Kingdom due to the 2019 Novel Coronavirus outbreak.
At 11:00 pm GMT on January 31, 2020, the United Kingdom formally left the European Union, completing a Brexit process that started in June 2016. As part of the transition period, the United Kingdom will remain in the European Union customs union and single market until December 31, 2020. During this time UK nationals will retain the right to reside and work in the European Union and vice versa, and freedom of movement between the European Union and the United Kingdom will continue.
The smooth functioning of international civil legal proceedings across European Union (EU) national frontiers has been one of the benefits of EU membership. With the United Kingdom (UK) now departing from the EU, are cross-border litigation cases going to encounter new obstacles?
Morgan Lewis consultant Paul Ranson discussed the latest developments in relation to medical devices in European Pharmaceutical Review. Paul noted the current and forthcoming regulatory updates and the potential implications of Brexit for medical device manufacturers and regulators.
Welcome to the Q3 2019 issue of our Life Sciences International Review. This issue covers new developments within Europe, Asia, and the United States in intellectual property, regulatory, pricing, and international trade, among others. Content for the newsletter was generated by Morgan Lewis lawyers. Many of these subjects will be updated in future issues as we will stay current with the continuous happenings and trends within the life sciences industry.
From disrupting the supply of medical devices to affecting how they are regulated and sold in the United Kingdom (UK), Brexit could carry significant implications for UK healthcare and trade.
Since the introduction of the EU Settlement Scheme earlier this year, the EU Exit: ID Document Check app has only been compatible with Android devices. Applicants without an Android device have been required to send their original documents to the Home Office or borrow an Android device in order to submit an application to the EU Settlement Scheme.
Employers should review the proposals setting out no-deal Brexit plans, immigration plans if the United Kingdom does adopt the proposals set out in the withdrawal agreement, and related considerations.
A statement of changes to the UK’s Immigration Rules was announced on 9 September. Here is a summary of the most relevant changes.
Following the prime minister’s announcement that free movement will come to an end, the UK government has published a policy paper setting out proposals for European Economic Area and Swiss nationals if the United Kingdom leaves the European Union without a deal on October 31, 2019.
A no-deal Brexit is now a very real possibility, and the UK government has announced that freedom of movement of EU citizens and their family members will come to an end immediately on 31 October 2019 should the United Kingdom leave the European Union without a deal. This means that EEA and Swiss nationals arriving after 31 October 2019 will not be able to live and work in the United Kingdom as they can do currently.
Recent immigration updates include additions to the shortage occupation list in the United Kingdom, a pilot scheme to facilitate employment pass applications for tech companies in Singapore, and a new work visa category in Japan for graduates of Japanese universities.
Welcome to the Q2 2019 issue of our Life Sciences International Review. This issue covers new developments within Europe, Asia, and the United States in intellectual property, regulatory, pricing, and international trade, among others. Content for the newsletter was generated by Morgan Lewis lawyers. Many of these subjects will be updated in future issues as we will stay current with the continuous happenings and trends within the life sciences industry.
The European Court of Justice (ECJ) ruled on 14 May in Federacion de Servicios de Comisiones Obreras v Deutsche Bank SAE, which called into question the validity of member states’ implementation of the European Union’s Working Time Directive (the Directive). The decision raises serious doubts as to the United Kingdom’s own compliance with the Directive.
Morgan Lewis consultant Paul Ranson looks at the potential implications for the life sciences sector following Brexit, with a focus on the Association of South Eastern Nations (ASEAN) region.
Welcome to the Q1 2019 issue of our Life Sciences International Review. This issue covers life sciences developments in the areas of intellectual property, regulatory, pricing and reimbursement, international trade, litigation, and competition that are of particular importance across Europe, Asia, and the United States. It also provides some of the latest information on Brexit.
Following the launch of the public testing phase on 21 January 2019, the EU Settlement Scheme (Scheme) fully launched on 30 March.
With the current UK withdrawal agreement voted down again, a possible Brexit extension is on the horizon. In addition, the UK Home Office has updated the immigration rules with two new startup and innovator categories, and increased fees for immigration and nationality applications. The EU has announced a pre-travel authorization system, and Ireland will grant spouses of critical skills permit holders the right to work.
The commercial and legal landscape in the United Kingdom is likely to experience considerable change as a result of Brexit. Its potential impacts have been widely discussed in recent months and years, and will include those resulting from a potentially significant fall in the value of the sterling, delay and cost caused by possible tariffs, and the uncertainty caused by the fact that a very large number of regulatory regimes are governed by EU law.
The UK government has published a policy paper setting out proposals for European Economic Area (EEA) and Swiss nationals if the United Kingdom and European Union do not reach a withdrawal agreement by March 29, 2019.
Welcome to the Q4 2018 issue of our Life Sciences International Review. This issue covers life sciences developments in the areas of intellectual property, regulatory, pricing and reimbursement, international trade, litigation, and competition that are of particular importance across Europe, Asia, and the United States. It also provides some of the latest information on Brexit.
This Financial Markets Law Committee report co-authored by partner Pulina Whitaker focuses on issues of legal uncertainty potentially hindering the continuation of the lawful flow of personal data between the UK, the European Economic Area and/or Third Countries following Brexit, as well as on the framework and mechanics for supervision and enforcement of the data protection regimes post-Brexit.
Welcome to the Q3 2018 issue of our Life Sciences International Review. This issue covers life sciences developments within Europe, Asia, and the United States in the areas of intellectual property, regulatory, pricing and reimbursement, international trade, litigation, and competition, and provides the latest on the ongoing Brexit saga.
As part of its preparations for a potential “no deal” scenario when the United Kingdom (UK) leaves the European Union (EU) on 29 March 2019, the UK Department for Digital, Culture, Media and Sport (DDCMS) has released guidance on “Data protection if there’s no Brexit deal”.
The UK government has published a Statement of Intent on how the EU Settlement Scheme will work for European Union nationals and their families to secure long-term status in the United Kingdom after its withdrawal from the European Union. EU nationals should take note of the application process to secure “settled status”, and employers should consider taking steps to ensure a smooth transition for their EU national employees when the UK leaves the EU.
Welcome to the Q2 2018 issue of our Life Sciences International Review, produced by our life sciences lawyers in the US, Europe, and Asia and covering some of the most critical developments in the pharmaceutical and medical technology sectors in the last month.
As part of Brexit negotiations, the European Union and the United Kingdom have now agreed in principle to a transition period during which the free movement of EU workers will continue; EU workers must complete a registration process within three months of their arrival in the United Kingdom. Among other immigration updates, the UK government has proposed increases to certain application fees, and Croatian nationals will no longer face restricted access to the UK labour market.
Welcome to the latest issue of our International Life Sciences Review, produced by our life sciences lawyers in the US, Europe and Asia and covering some of the most critical developments in the pharmaceutical and medical technology sectors in the last month. If you have questions on any of these topics, please contact please contact Paul Ranson.
The UK Home Office published a Statement of Changes to the Immigration Rules, including a reduced waiting period for graduating students to switch from Tier 4 to Tier 2 and the proposed issuance of electronic entry clearances.
Employers should audit the immigration status of their workforce, review long-term recruitment, and take a number of other steps to manage risks and ensure a smooth transition into a post-Brexit world.
Paul Ranson, Consultant in the London office, dissects Sir John Bell’s industrial strategy in the context of the UK’s departure from the European Union.
Aware of the risks of regulatory arbitrage developing post-Brexit, a key feature of the Commission’s proposals allows ESAs to monitor the practices of EU27 regulators.
Welcome to the latest issue of our European Life Sciences Review, produced by our life sciences lawyers in London, Brussels, Frankfurt, Moscow, and Paris and covering some of the most critical developments in the pharmaceutical and medical technology sectors in the last month. If you have questions on any of these topics, please contact Paul Ranson.
The European Securities and Markets Authority foresees regulatory and arbitrage risks in Brexit and has issued an opinion as a practical tool to help achieve supervisory convergence among EU regulators—Brexit negotiations begin on June 19, and Brexit is scheduled to occur on or before March 30, 2019 unless an extension is agreed.
Law360, New York (May 5, 2017, 10:21 AM EDT) -- The British government has determined that its exit from the European Union also must include withdrawal from the European Atomic Energy Community (Euratom). According to a British government white paper, the 2008 EU Amendment Act provides that: "A reference to the EU in an Act or an instrument made under an Act includes ... a reference to [Euratom]."
The UK’s data protection laws are derived from EU legislation, such as the Data Protection Act 1998 (“DPA”) and the Privacy and Electronic Communications Regulations which implement European Directives.
Welcome to the sixth issue of our EU Life Sciences Review, which covers some of the most critical developments in the pharmaceutical and medical technology sectors in the last quarter and is produced by our life sciences lawyers in London, Frankfurt, Paris, and Moscow.
Our goal with this article is to provide asset managers with the current state of Brexit so that they can continue to assess its potential impact on their businesses.
The UK government intends to ratify the Unitary Patent System and the Unified Patent Court prior to Brexit.
While the swirl of day-by-day posturing, partisan commentary, and reluctance of the UK and EU authorities to reveal their negotiating hands make it challenging to discern probable routes forward and plan accordingly, there is no reason why even a "hard Brexit" cannot encompass access to the single market for financial services companies.
This article seeks to summarize what Brexit could mean for the U.K. and EU pharmaceutical and medical device sectors.
It may come as no surprise that a pre-referendum ‘Brexit” poll conducted by the UK Pharmaceutical Directors Club of senior management within the UK pharmaceutical industry resulted in a vast majority in favour of “Remain” with local management and head offices concerned about the possibility of the UK exiting the European Union (EU) and negative implications for their businesses.
Since passage of the Drug Supply Chain and Security Act (DSCSA) of 2013, Section 582 of the Federal Food, Drug and Cosmetic Act (FFDCA) (21 U.S.C. § 360eee-1), pharmaceutical product manufacturers have been implementing systems and processes to track and trace drug product through the drug supply chain in the US.
It may come as no surprise that a pre-referendum ‘Brexit” poll conducted by the UK Pharmaceutical Directors Club of senior management within the UK pharmaceutical industry resulted in a vast majority in favour of “Remain” with local management and head offices concerned about the possibility of the UK exiting the European Union (EU) and negative implications for their businesses.
Simon Currie, private investment funds partner at global law firm Morgan Lewis, examines how 'third country regimes' work and the implications for asset managers if an independent UK was allowed access to the EU single market.
The new regime shares the same aims as its predecessor—to ensure the integrity of EU financial markets and enhance investor confidence—and keeps pace with market developments such as new trading platforms, new technology, and the upcoming overhaul of market regulation under MIFID II due early 2018.
Pharmaceutical and agricultural companies in particular should consider the effect of Brexit on their European patent portfolios.
Much attention has focused on access to the EU single market requiring acceptance of free movement of people but, in two important areas of the financial services sector, this is not the case. Simon Currie, author.
On 23 June, 52% of UK voters voted in favour of leaving the European Union, which has generated considerable uncertainty about the United Kingdom’s future relationship with Europe and, as a result, the wider world, including Singapore.
Although no changes will affect competition law and enforcement in the immediate future, the long-term implications of Brexit depend on the relationship between the United Kingdom and the European Union.
Following the United Kingdom’s nonbinding vote to leave the European Union (“Brexit”), what do businesses need to consider for data privacy compliance?
Does the United Kingdom’s vote to leave the European Union change the United Kingdom’s attractiveness as a holding company jurisdiction?
UK law after the referendum.
While the “Leave” result of the June 23 referendum will not have an immediate impact on intellectual property, the eventual British exit (“Brexit”) from the European Union could have long-term implications for IP protection and filing decisions in Europe.
As we stand only weeks away from the United Kingdom’s referendum on a potential cleaving from the European Union, economists and politicians are busy analyzing the potential effects of either decision; there are also potential ramifications for the legal world.
With the referendum for Britain potentially leaving the European Union (“Brexit”) fast approaching on 23 June 2016, a “leave” vote could have far-reaching consequences for commercial litigation in the courts of England and Wales.
If Britain decides to leave the European Union as a result of a “Brexit” vote on 23 June 2016, the effect on the UK and EU financial services sectors could be significant; in particular, there could be effects on the London Stock Exchange (LSE) listing regime, which potentially (but not necessarily) would no longer be subject to the Prospectus Directive and other EU legislation related to securities listings.
UK Prime Minister David Cameron has announced a referendum on whether Britain should remain in the EU to be held on Thursday 23 June 2016. As the ‘in’ and ‘out’ sides marshal their arguments, businesses and in particular the life sciences sector are giving thought to what would happen if the UK chose to leave the EU.
A “leave” vote on 23 June 2016 could have significant impact on employee and individual mobility, immigration, and UK citizenship status.
Should Britain decide to leave both the EU and EEA as a result of a “Brexit” vote on 23 June 2016, the impact on UK and EU financial services firms could be significant.
As the June 23 referendum on Britain’s membership in the European Union looms, the potential that Britain will exit the European Union (“Brexit”) raises data privacy issues.
The potential that Britain will exit the European Union (“Brexit”) after an upcoming referendum on June 23 raises issues for employers.
In The News
Partner Pulina Whitaker spoke with Global Data Review about the UK government’s plan to introduce its new Data Reform Bill.
Partner Pulina Whitaker spoke to Legaltech News about her outlook for privacy law in the upcoming year.
Leonidas Theodosiou was quoted in a Global Competition Review article regarding the United Kingdom’s new Subsidy Control Bill that was introduced in Parliament.
Partner Pulina Whittaker was quoted in a Law360 article about the Trade and Cooperation Agreement, which maintains an arrangement for data transfer between companies in the European Union and the United Kingdom.
Morgan Lewis partner Sabine Konrad was interviewed by the International Financial Law Review for an article about bilateral investment treaties after Brexit.
Jeffry Mann and Paul Ranson provide their perspectives on how discussions around Brexit are affecting life sciences companies and the potential future implications.
Morgan Lewis partner William Yonge discusses the implications for financial services of a “no-deal” Brexit.
Shareholders of Dr Pepper Snapple Group Inc. do not have appraisal rights in the proposed $21 billion merger of the company with Keurig Green Mountain Inc., after a Delaware Chancery Court judge ruled Friday that Dr Pepper itself is not a party to the deal.
Law360 interviews Morgan Lewis partner William Yonge about a draft treaty the European Union has signed with Britain on its exit from the bloc, including a 21-month transition deal.
Investment firms may have to move thousands of jobs to the European Union after regulators said “letterbox entities” nominally based in the EU but run from abroad will not be tolerated, lawyers and advisers say. Simon Currie is quoted.
The UK was one of the dissenting voices in negotiations about the regulations. Pulina Whitaker quoted on Brexit and data privacy.
Following Prime Minister Theresa May’s Brexit plan speech in February 2017, Bruce Johnston was quoted in Legal Business.
Following Prime Minister Theresa May’s Brexit plan speech, Bruce Johnston was quoted in Finance Monthly noting,"There are no plans for an overall transitional deal, but there may be interim arrangements to minimise disruption for certain sectors of the economy."
In December 2016, Bruce Johnston commented on Brexit negotiations in The Times.
For Philadelphia law firms with a large European footprint, the surprising aftermath of the Brexit vote in June was that there wasn’t much of an aftermath. Torsten Schwarze quoted.
Passporting is claimed to be impossible without freedom of movement. But is that entirely true? Look more closely and the regulations are not always what they seem. Simon Currie quoted.
Simon Currie is quoted, noting he "does not think an exodus is necessary. It says the passport 'is not a prerequisite for assessing the single markets' for alternative investments as most providers satisfy 'equivalence' regimes."
Britain isn’t the only place affected by ‘Brexit’: Philadelphia businesses with dealings overseas are also looking for guidance as the United Kingdom prepares to leave the European Union. Michael Pedrick quoted.
In taking the UK out of AIFMD jurisdiction, Brexit could offer American GPs easier access to British capital. Simon Currie quoted.
The UK’s vote to leave the European Union has spurred multinationals in the UK, Europe, North America and Asia to reconsider their operations in Britain. Anjana Haines looks at the potential tax implications of a post-Brexit UK and its relationship with the EU. Tax Partner Kate Habershon is quoted.
The Wall Street Journal (Europe) writes about the UK’s access the European Union's single market in the wake of Brexit. Simon Currie explains that rules that apply specifically to hedge funds and some investment managers provide a means by which non-EU countries can gain a stamp of approval to sell into the bloc.
UK hedge funds and investment managers could still access the European Union’s ‘single market’ in the wake of a Brexit without having to sign up to the bloc’s core principles on migration, say lawyers. Simon Currie quoted.
Cross-border deals, a big source of revenue for law firms in Philadelphia and beyond, likely will take a hit from the British vote to exit the European Union, lawyers who specialize in international transactions say. Floyd Wittlin quoted.
A failure of the UK to join the European Economic Area, following last week’s Brexit decision, could have serious implications of the fund management industry, according to the London office of global law firm Morgan Lewis. William Yonge and Simon Currie quoted.
The United Kingdom's June 23 vote to leave the European Union threw global markets into turmoil. According to Morningstar’s equity analysts, the effect of Britain's exit—or Brexit—on the stocks they cover will vary by sector and even by company.
Uncertainty over the vote's meaning may derail some existing deals and complicate new ones. Also covered by The Street. Iain Wright quoted.
FIA has compiled a variety of resources that may of be interest to industry members as the United Kingdom (U.K.) has voted in favour of leaving.
Morgan Lewis partner William Yonge discusses long-term risks to banks and hedge funds. William Yonge quoted.
London's long reign as Europe's financial center will end — along with thousands of jobs —if the United Kingdom pulls out of the European Union, banking and business leaders warn. Simon Currie quoted.
Britons travelling on continental Europe could be stripped of legal protections when they suffer injuries if the UK leaves the EU, a specialist law firm warned, as lawyers rushed to get their last shots in before tomorrow’s referendum. Peter Sharp quoted.
With the referendum for Britain potentially leaving the EU (Brexit) fast approaching on 23 June 2016, a ‘leave’ vote could have far-reaching commercial litigation consequences for England and Wales. Authored by Nicholas Greenwood and Paul Mesquitta.
The UK and its European siblings are caught in the midst of a family row that could turn sour this week, if the island nation votes to leave the protection of the European Union and strike out alone. Ayman Khaleq quoted.
Ahead of a Thursday vote as to whether Britain should exit the European Union, questions have arisen as to how such a move could impact London's prominence in international arbitration. Here, Law360 takes a look at what international arbitration attorneys need to know about a possible vote in favor of the so-called Brexit. David Waldron quoted.
With George Soros and other market analysts and experts predicting a market meltdown should the UK decide to leave the European Union, our analysis for today looks at some of the issues that the UK will have to face whether it remains or leaves the European Union. Includes commentary from Simon Currie and William Yonge.
Should Britain decide to leave the EU and not to join the European Economic Area (EEA) as a result of a ‘Brexit’ vote on 23 June 2016, the impact on UK and EU financial services firms could be significant. Authored by Simon Currie and William Yonge.
As the UK’s 23 June referendum on continued EU membership creeps closer, many will understandably feel they’re as far as they ever were from understanding what a post-Brexit world might look like.
The Economist provides a comprehensive background overview of Britain’s June 23 referendum on its membership in the European Union, delving into the underlying motivations and machinations that led to the potential for “Brexit.” The piece provides helpful infographics that lay out the arguments on the “leave” and “remain” sides, including key migration and export data central to the debate.
Other Brexit Coverage
Financial Times
Brexit Business Tracker (continuously updated)
Brexit: The Big Questions Answered (27 June 2016) (subscription required)
Wall Street Journal
U.K.’s EU Exit Poses Data-Protection Dilemma (30 June 2016) (subscription required)
What ‘Brexit’ Means for U.S. Investors (26 June 2016) (subscription required)
The Times
Article 50: Understanding the Legal Architecture Around Brexit (30 June 2016) (subscription required)
Morningstar
Financial Services: Accounting for Brexit and the Fiduciary Rule (30 June 2016)
Telegraph
Will Brexit Mean I Can No Longer Work in Britain? (30 June 2016)
BBC
Brexit: What Happens Now? (29 June 2016)
Bloomberg
Investors Map Post-Brexit Strategies Amid Global Market Upheaval (26 June 2016)
The Guardian
What is Article 50 and Why is it so Central to the Brexit Debate? (25 June 2016)
Politico
How the UK Exit Will Work - Four Ways the British Government Could Approach Quitting the Bloc. (24 June 2016)
Past Events
Please join our immigration lawyers for an update on Brexit, what it means for employers now, and what to expect in the future.
The presentation will cover where we are in the Brexit negotiations and what this means for tech companies currently employing EU nationals in the UK. We will go over steps that they should be taking now to ensure that these employees will continue to have the right to remain in the UK, what the rules might be after Brexit, and how this might impact tech companies sending individuals to the UK.
Forthcoming changes to regulation governing the provision and receipt of research are among the most influential aspects of MiFID II in shaping the financial markets landscape.
Bruce Johnston, presenter
In conjunction with the British American Business Council (BABC) of Greater Philadelphia please join us for an informative session about the implications of Brexit.
Please join us for the 18th installment of our What We’re Seeing webinar series, featuring updates on hot topics and trends that you should follow. This webinar will focus on important developments regarding employee benefits and executive compensation.
Please join us for a one-hour webinar to discuss the implications for US asset managers in the wake of the United Kingdom’s vote to leave the European Union.
Join us for a one-hour webinar to discuss the employment, data privacy, and employee mobility considerations in the wake of the United Kingdom’s vote to leave the European Union. We will discuss the anticipated effect of Brexit for employers, review possible consequences for employee mobility, and consider potential changes to UK laws.
Please join us for a one-hour webinar to discuss the implications for US asset managers in the wake of the United Kingdom’s vote to leave the European Union.
The Morgan Lewis Brexit Resource Centre and brexit@morganlewis.com do not constitute, and are not intended to constitute, legal advice with respect to any particular circumstance and do not create an attorney-client relationship with Morgan Lewis. The contents are intended for general information purposes only, and the invitation to contact us is not a solicitation for legal work under the laws of any jurisdiction in which Morgan Lewis lawyers are not authorized to practice.
By sending a communication to brexit@morganlewis.com, you acknowledge and agree that Morgan Lewis’s review of the information contained in your e-mail, and any attachment thereto, will not create an attorney-client relationship, or preclude any attorney at Morgan Lewis from representing a party in any matter where that information is relevant. Further, while we welcome your inquiries, please do not include in your message to brexit@morganlewis.com any confidential or sensitive information or data.
Copyright © 2022 Morgan, Lewis & Bockius LLP. All rights reserved.